BOTANIX PHARMACEUTICALS LIMITED (BOT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BOT - BOTANIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences

Year End: June

GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences

Debt/EBITDA: -0.4

Index: ASX300 | ALL-ORDS

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$0.11 03 Feb 2026	0.010 OPEN $0.11	10.00% HIGH $0.11	2,260,580 LOW $0.10

LAST PRICE

CHANGE +/-

CHANGE %

VOLUME

$0.11

03 Feb
2026

0.010

OPEN

$0.11

10.00%

HIGH

$0.11

2,260,580

LOW

$0.10

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . AVH . BIO . COV . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .

FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2026 FactSet UK Limited. All rights reserved

Title	2020	2021	2022	2023	2024	2025
EPS Basic	xxx	xxx	xxx	xxx	xxx	-4.7
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	6.5 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	4.1
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	-78.6 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-1,332.69 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title	2020	2021	2022	2023	2024	2025
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-90.93 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-81.16 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-71.53 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-90.93 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-74.68 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	-78.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title	2020	2021	2022	2023	2024	2025
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	9 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	23 M
Total Debt	xxx	xxx	xxx	xxx	xxx	32 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	-
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	65 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	7.72

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title	2020	2021	2022	2023	2024	2025
Capex	xxx	xxx	xxx	xxx	xxx	1.0 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	16.19 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	78 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	12 M
Research & Development	xxx	xxx	xxx	xxx	xxx	0 M
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Canaccord Genuity	27/01/2026	1	Buy	$0.24	118.18%	Botanix Pharmaceuticals’ 2Q26 result fell short of expectations, with net sales of $9.1m around -13% below Canaccord Genuity’s forecast despite 29% quarter on quarter growth Script volumes increased 24% to 25,351, but this was still a -15% miss to the broker’s estimate, while gross to net yield improved modestly to 24%, below expectations. Cash outflows of -$17.2m were higher than forecast, reflecting one off SG&A costs linked to the expansion of the US sales force from 27 to around 50 representatives. Buy is retained with an unchanged target price of $0.24, although the broker flags ongoing volatility and capital overhang risks through the remainder of FY26. FORECAST Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.10 cents. Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.60 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Canaccord Genuity

27/01/2026

Buy

$0.24

118.18%

Botanix Pharmaceuticals’ 2Q26 result fell short of expectations, with net sales of $9.1m around -13% below Canaccord Genuity’s forecast despite 29% quarter on quarter growth

Script volumes increased 24% to 25,351, but this was still a -15% miss to the broker’s estimate, while gross to net yield improved modestly to 24%, below expectations.

Cash outflows of -$17.2m were higher than forecast, reflecting one off SG&A costs linked to the expansion of the US sales force from 27 to around 50 representatives.

Buy is retained with an unchanged target price of $0.24, although the broker flags ongoing volatility and capital overhang risks through the remainder of FY26.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.10 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.60 cents.

Access Extra Coverage Research History >

BOT STOCK CHART

FNArena News on BOT

Latest Pharmaceuticals & Biotech/Lifesciences News

1	CSL: Buy Trigger Ahead Apr 26 2022 - Technicals

2	Why CSL Fell Sharply Yesterday Dec 17 2021 - Australia

3	Beating The Biotech Blues Sep 14 2021 - International

4	Uncertainty Prevails For CSL Aug 19 2021 - Australia

5	Flying High – Medicinal Marijuana In Australia Jul 26 2021 - Australia

6	Wesfarmers On Drugs? Jul 13 2021 - Australia

7	Is CSL’s Plasma Recovery Now Priced In? Jun 23 2021 - Australia

8	CSL: Buy The Dip Jun 22 2021 - Technicals

9	CSL To Retest Its High? May 25 2021 - Technicals

10	Treasure Chest: CSL Plasma At Turning Point? May 05 2021 - Treasure Chest

Get 2 Weeks free trial

Sign Up

Member Login

BOTANIX PHARMACEUTICALS LIMITED (BOT)
Share Price Analysis and Chart